In the article “Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients”[1] that appeared on pages e506-e509 of the December 2021 issue of The Pediatric Infectious Disease Journal, the authors would like to acknowledge the following:Children’s National Emergency Department Contributors:Amie Cahill, MD* Josh Heffren, PharmD, BCPPS†*Divisions of Emergency Medicine, †Division of Pharmacy Services.